Expression and prognosis of N-α-acetyltransferase gene 10 in breast cancer

Objective To study the possibility of protein acetyltransferase gene 10 (NAA10) as a target for breast cancer treatment. Methods Based on METABRIC database, 1974 cases of breast cancer patients were selected, including 718 cases of Luminal A subtype, 488 cases of Luminal B subtype, 240 cases of human epidermalgrowth factor receptor-2 (Her-2) subtype, 329 cases of basal-like subtype, and 199 cases of normal-like subtype. Using METABRIC database, the relationship between 33 acetyltransferase genes and the prognosis of breast cancer, and the relationship between NAA10 gene expression and clinicopathological parameters of breast cancer were studied. NAA10 small interfering RNA (siRNA) was used to treat breast cancer cell lines with NAA10 high expression, and the effect of NAA10 gene silencing on breast cancer cell proliferation was detected by cell counting kit-8 (CCK-8) and plate clone formation assays. Results The mRNA expression of NAA10 was significantly correlated with the disease-free survival rate (DFS) and overall survival rate of breast cancer (P<0.05), and the relative risk ratios were 1.31 (1.14-1.51) and 1.13 (1.01-1.25), respectively. NAA10 gene expression was positively correlated with breast cancer histological grade, lymph node status, and Nottingham index (NPI) (P<0.01). NAA10 mRNA and protein levels were highest in Basal-like breast cancer. Compared with control group, NAA10 gene silencing inhibited 50% breast cancer cell proliferation (P<0.05). Conclusion NAA10 gene is closely related to breast cancer cell proliferation and its expression level is closely related to breast cancer prognosis. NAA10 gene may become a target for future treatment of breast cancer. Key words: N-α-acetyltransferase gene 10; Lysine acetyltransferase; Small interfering RNA; Breast cancer